Emergent Biosolutions, Inc. (EBS)
Emergent BioSolutions, Inc. (EBS) is a biotechnology company focused on developing, manufacturing, and delivering specialized products for public health threats. Founded in 1998, the company primarily provides vaccines, therapeutics, and other health solutions targeting infectious diseases, biodefense, and emerging threats. Emergent collaborates with government agencies, such as the CDC and BARDA, to support national preparedness and response efforts.
Company News
Emergent BioSolutions has completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International for approximately $36.5 million. The deal enables Emergent to streamline operations while maintaining flexibility for future product demand.
Emergent BioSolutions and Rocketvax have announced a strategic partnership, where Emergent will invest in Rocketvax and lead the U.S. manufacturing and commercialization of four of Rocketvax's pipeline candidates for infectious diseases, cancer, and autoimmune disorders.
Emergent BioSolutions stock surged nearly 12% after an analyst at H.C. Wainwright initiated coverage with a buy recommendation and a $15 price target, citing the company's diversified offerings and growth potential in its Narcan opioid reversal spray and vaccines business.
The article discusses three pharmaceutical companies with potential to meet the demand for mpox vaccines: Bavarian Nordic, Emergent Biosolutions, and SIGA Technologies. It highlights their vaccine and treatment candidates, recent developments, and stock performance.
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
